Docket No. ORT-1453

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

# Listing of Claims:

Claims 1-11 (canceled)

Claim 12 (currently amended) A The method of claim 10 for treating impaired oral glucose tolerance in a mammal afflicted with such condition comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:

$$R^5$$
 $X$ 
 $CH_2OSO_2NHR^1$ 
 $R^2$ 
 $R^4$ 
 $R^3$ 
 $(I)$ 

### wherein

X is CH2 or oxygen;

R1 is hydrogen or alkyl; and

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently hydrogen or lower alkyl and, when X is CH<sub>2</sub>, R<sup>4</sup> and R<sup>5</sup> may be alkene groups joined to form a benzene ring and, when X is oxygen, R<sup>2</sup> and R<sup>3</sup> and/or R<sup>4</sup> and R<sup>5</sup> together may be a methylenedioxy group of the following formula (II):

$$\begin{array}{c|c}
R^6 & O \\
\hline
R^7 & O \\
\hline
\end{array}$$
(III)

#### wherein

R<sup>6</sup> and R<sup>7</sup> are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or

Docket No. ORT-1453

cyclohexyl ring, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.

- Claim (13) (currently amended) The method of claim 1012, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- 3 Claim (14) (currently amended) The method of claim 1012, wherein the amount is of from about 16 to 325 mg once or twice daily.

Claims 15-21 (canceled)

Claim 22 (currently amended) AThe method of Claim 20 for improving defective insulin sensitivity in a mammal afflicted with such condition with comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:

$$\begin{array}{c|c}
R^5 & \xrightarrow{X} CH_2OSO_2NHR^1 \\
\hline
R^4 & R^3 & (I)
\end{array}$$

## wherein

X is CH2 or oxygen;

R1 is hydrogen or alkyl; and

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently hydrogen or lower alkyl and, when X is CH<sub>2</sub>, R<sup>4</sup> and R<sup>5</sup> may be alkene groups joined to form a benzene ring and, when X is oxygen, R<sup>2</sup> and R<sup>3</sup> and/or R<sup>4</sup> and R<sup>5</sup> together may be a methylenedioxy group of the following formula (II):

$$\begin{array}{c|c}
R^6 & O \\
\hline
R^7 & O \\
\hline
\end{array}$$
(II)

Docket No. ORT-1453

#### wherein

R<sup>6</sup> and R<sup>7</sup> are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.

- 6 Claim (23) (currently amended) The method of claim 2022, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- Claim (24) (currently amended) The method of claim 2022, wherein the amount is of from about 16 to 325 mg once or twice daily.